NEUMORA THERAPEUTICS INC (NMRA) Stock Income Statement
NASDAQ:NMRA - Nasdaq - US6409791000 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 274.33M | 263.46M | 188.19M | 122.87M | 80.32M | |||
| Research and Development | 207.32M | 200.93M | 142.72M | 91.75M | 55.78M | |||
| Selling, General, and Administrative Expenses | 67.00M | 62.54M | 45.48M | 31.12M | 24.55M | |||
| Operating Income | -274.33M | -263.46M | -188.19M | -122.87M | -80.32M | |||
| Interest Income/Expense | 16.64M | 19.93M | 16.61M | 4.56M | 0.00 | |||
| Other Income/Expense | -91.00K | -78.00K | -170.00K | 410.00K | 10.00K | |||
| Non Recurring Items | N/A | N/A | -63.90M | -13.00M | -157.00M | |||
| Income Before Taxes | -257.77M | -243.61M | -235.66M | -130.90M | -237.31M | |||
| Income Tax | 283.00K | 178.00K | 268.00K | N/A | N/A | |||
| Net Income | -258.06M | -243.79M | -235.93M | -130.90M | -237.31M | |||
| EBITDA | -273.70M | -262.83M | -187.53M | -122.28M | -79.78M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -1.61 | -1.53 | -1.49 | -0.86 | -1.56 | |||
| Non GAAP EPS | -1.61 | -1.53 | N/A | N/A | N/A | |||
| Statistics | ||||||||
All data in USD